Company
Headquarters: Nanjing, China
Employees: 763
CEO: Dr. Wenfang Miao Ph.D.
CN¥9.37 Billion
CNY as of Jan. 1, 2026
US$1.34 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥1.98 B |
| EBITDA | CN¥342.0 M |
| Gross Profit TTM | CN¥573.9 M |
| Profit Margin | 10.16% |
| Operating Margin | 18.94% |
| Quarterly Revenue Growth | 30.40% |
PharmaBlock Sciences has the following listings and related stock indices.
Stock: SZSE: 300725 wb_incandescent